Priorities for the treatment of latent tuberculosis [3] (multiple letters)

New England Journal of Medicine

Volumn 351, Issue 8, 2004, Pages 832-834

  Taylor, William C ^a   Tsevat, Joel ^b   Pauker, Stephen G ^c   Charles, Macarthur ^d   Rhee, Kyu Y ^d   Marks, Guy B ^e   Britton, Warwick J ^f   Horsburgh Jr , C Robert ^g  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULIN; TUBERCULOSTATIC AGENT;

HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LETTER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SKIN TEST; TUBERCULOSIS; NOTE; RISK FACTOR; TUBERCULIN TEST; COST OF ILLNESS;

ANTITUBERCULAR AGENTS; HUMANS; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS; COST OF ILLNESS;

EID: 4143108093     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200408193510823     Document Type: Letter

References (0)